2123480-72-6
2123480-72-6 structure
- Name: UbcH5c-IN-1
- Chemical Name: UbcH5c-IN-1
- CAS Number: 2123480-72-6
- Molecular Formula: C22H21BrO3
- Molecular Weight: 413.30
- Catalog: Signaling Pathways Metabolic Enzyme/Protease E1/E2/E3 Enzyme
- Create Date: 2019-03-30 18:54:34
- Modify Date: 2024-01-08 18:44:35
-
UbcH5c-IN-1 (compound 6d) is a potent and selective small-molecule inhibitor of Ubiquitin-conjugating enzyme UbcH5c, with a Kd of 283 nM for E2 UbcH5c-IN-1 by covalent binding with Cys85. A promising lead compound for the development of new antirheumatoid arthritis (RA) agent[1].
| Name | UbcH5c-IN-1 |
|---|
| Description | UbcH5c-IN-1 (compound 6d) is a potent and selective small-molecule inhibitor of Ubiquitin-conjugating enzyme UbcH5c, with a Kd of 283 nM for E2 UbcH5c-IN-1 by covalent binding with Cys85. A promising lead compound for the development of new antirheumatoid arthritis (RA) agent[1]. |
|---|---|
| Related Catalog | |
| Target |
Kd: 283 nM (E2 UbcH5c)[1]. |
| In Vivo | UbcH5c-IN-1 (compound 6d) (5 and 20 mg/kg, p.o., daily, 10-20 days) treatment in Freund’s adjuvant (CFA)-induced adjuvant arthritis (AA) rat model results in appreciable decreases in the arthritis index score and hind paw swelling rate compared with those of the vehicle-treated AA model control group[1]. Animal Model: Freund’s adjuvant (CFA)-induced adjuvant arthritis (AA) rat model[1]. Dosage: 5 and 20 mg/kg Administration: Oral administration daily between day 10-20 postimmunization. Result: Resulted in appreciable decreases in the arthritis index score and hind paw swelling rate compared with those of the vehicle-treated AA model control group. |
| References |
| Molecular Formula | C22H21BrO3 |
|---|---|
| Molecular Weight | 413.30 |